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A B  S T R AC T  The cystic fibrosis transmembrane conductance regulator (CFTR) is a 
C1- channel that is regulated by cAMP-dependent phosphorylation and by intracel- 
lular ATP. Intracellular ATP also regulates a class of K + channels that have a distinct 
pharmacology: they are inhibited by sulfonylureas and activated by a  novel class of 
drugs called K ÷ channel openers.  In search of modulators of CFTR CI- channels, 
we  examined  the  effect of sulfonylureas and  K +  channel  openers  on  CFTR  CI- 
currents in cells expressing recombinant CFTR. The sulfonylureas, tolbutamide and 
glibenclamide, inhibited whole-cell CFFR CI- currents at half-maximal concentra- 
tions  of  ~  150  and  20  o.M,  respectively. Inhibition by both  agents  showed  little 
voltage dependence and developed slowly;  > 90%  inhibition occurred 3  rain after 
adding 1 mM tolbutamide or I00 0.M glibenclamide. The effect of tolbutamide was 
reversible, while that of glibenclamide was not. In contrast to their activating effect 
on  K +  channels,  the  K +  channel  openers,  diazoxide, BRL  38227,  and  minoxidil 
sulfate inhibited CFTR CI- currents. Half-maximal inhibition was observed at ~ 250 
~M diazoxide, 50 o.M BRL 38227, and 40 ~M minoxidil sulfate. The rank order of 
potency for inhibition of CFTR CI- currents was: glibenclamide >  BRL 38227  - 
minoxidil sulfate  >  tolbutamide  >  diazoxide. Site-directed mutations of CFFR in 
the first membrane-spanning  domain  and  second nucleotide-binding domain did 
not affect glibenclamide inhibition of CFFR CI- currents.  However, when  part of 
the  R  domain  was  deleted,  glibenclamide  inhibition  showed  significant voltage 
dependence.  These  agents,  especially glibenclamide, which was  the  most  potent, 
may be of value in identifying CFTR C1- channels. They or related analogues might 
also prove to be of value in treating diseases such as diarrhea, which may involve 
increased activity of the CFTR CI- channel. 
INTRODUCTION 
Mutations  in  a  single  gene  encoding  cystic  fibrosis  transmembrane  conductance 
regulator (CFTR) cause the disease cystic fibrosis (CF) (Riordan,  Rommens,  Kerem, 
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Alon,  Rozmahel, Grzelczak,  Zielenski,  Lok,  Plavsic, Chou et al.,  1989). Amino acid 
sequence analysis and comparison with other proteins suggests that CFTR consists of 
five domains: two membrane-spanning domains, each composed of six transmem- 
brane  segments;  an  R  domain,  which  contains  several  consensus  sequences  for 
phosphorylation by  cAMP-dependent  protein  kinase  (PKA); and  two  nucleotide- 
binding domains (NBDs), which are predicted to interact with ATP.  Such  analyses 
also  suggest that CFI'R belongs to a  family of proteins that have been called the 
traffic ATPases (Ames, Mimura, and Shyamala,  1990) or the ABC transporters (Hyde, 
Emsley, Hartshorn, Mimmack,  Gileadi,  Pearce,  Gallagher, Gill, Hubbard, and Hig- 
gins, 1990). Some members of this family hydrolyze  ATP to transport substrate across 
cell membranes. 
Recent work suggests that CF-FR is a CI- channel. That conclusion is based on four 
observations.  First,  expression of recombinant CFTR in a wide variety of epithelial 
and nonepithelial cells generated cAMP-activated CI- channels (Drumm, Pope, Cliff, 
Rommens,  Marvin,  Tsui,  Collins,  Frizzell,  and  Wilson,  1990; Rich,  Anderson, 
Gregory, Cheng, Paul, Jefferson, McCann, Klinger, Smith, and Welsh,  1990; Ander- 
son,  Rich,  Gregory,  Smith,  and  Welsh,  1991c; Bear,  Duguay,  Naismith,  Kartner, 
Hanrahan, and Riordan, 1991 ; Kartner, Hanrahan, Jensen, Naismith, Sun, Ackerley, 
Reyes,  Tsui,  Rommens,  Bear,  and  Riordan,  1991). Second,  the  properties  of 
cAMP-regulated CI-  channels generated by recombinant CFTR were  the  same as 
those of cAMP-regulated  C1- channels in the apical membrane of secretory epithelia, 
where  the  CF  defect is  located  (Anderson,  Sheppard,  Berger,  and Welsh,  1992). 
Third, mutation of specific basic residues within the membrane-spanning domains to 
acidic residues altered the channel's anion selectivity (Anderson,  Gregory, Thomp- 
son,  Souza,  Paul,  Mulligan,  Smith,  and  Welsh,  1991b). Fourth,  when  purified 
recombinant CFFR was incorporated into planar lipid bilayers it displayed regulated 
C1- channel activity (Bear,  Li, Kartner, Bridges, Jensen, Ramjeesingh, and Riordan, 
1992). 
The CFTR CI- channel is regulated by cAMP: in experiments using the whole-cell 
and  cell-attached  configurations  of  the  patch-clamp  technique,  cAMP agonists 
activated CFTR C1- currents (Drumm et al.,  1990; Rich et al.,  1990; Anderson et al., 
1991c; Bear et al.,  1991; Berger, Anderson, Gregory, Thompson, Howard, Maurer, 
Mulligan, Smith, and Welsh, 1991; Kartner et al., 1991; Tabcharani, Chang, Riordan, 
and Hanrahan, 1991). This regulation occurs via phosphorylation, since addition of 
the catalytic  subunit of cAMP-dependent protein kinase to the cytosolic surface  of 
excised inside-out membrane patches activated CFFR CI-  channels (Berger et al., 
1991;  Tabcharani  et  al.,  1991). The  R  domain  is  the  site  of  PKA-dependent 
regulation because four serine residues in the R domain are phosphorylated in vivo 
when cellular  levels of cAMP increase (Cheng, Rich, Marshall,  Gregory, Welsh, and 
Smith,  1991). Mutation  of those  serines  to  alanines  abolishes  cAMP-dependent 
activation (Cheng et al., 1991). Moreover,  expression of CFTR in which part of the R 
domain has been deleted produces C1- channels that are constitutively active; that is, 
channel  activation  does  not  require  an  increase  in  cellular  cAMP levels  (Rich, 
Gregory, Anderson, Manavalan,  Smith, and Welsh,  1991). 
Nucleoside triphosphates, such as ATP, also regulate the CFFR CI- channel: once 
phosphorylated by PKA, micromolar concentrations of ATP are required to maintain SHEPPARD AND WELSH  K-ATP Channel Regulators Inhibit  CFTR  575 
channel activity (Anderson,  Berger,  Rich,  Gregory, Smith,  and Welsh,  1991a).  ATP 
activates the channel via a mechanism independent of both PKA and the R domain; 
regulation at the NBDs is an attractive explanation for this effect. 
Intracellular ATP also regulates a class of K + channels (ATP-sensitive K + channels; 
K-ATP channels) (Noma,  1983; Cook and Hales,  1984; Ashcroft and Ashcroft,  1990). 
The opening of K-ATP channels in pancreatic [3 cells, myocytes, and some neurons is 
coupled  to  the  cytoplasmic  concentration  of ATP.  In  contrast  to  the  CFTR  C1- 
channel where ATP activates the channel,  micromolar concentrations of ATP inhibit 
K-ATP channels  (Ashcroft  and Ashcroft,  1990).  Although  the  primary structure  of 
K-ATP channels  is presently unknown,  their regulation  by ATP suggests  that  they 
may share some similarity with CFTR CI- channels. 
K-ATP channels have a distinct pharmacology: they are inhibited by sulfonylureas, 
such  as  tolbutamide  and  glibenclamide,  a  group  of hypoglycemia-inducing  drugs 
used  to  treat diabetes  mellitus  (Sturgess,  Ashford,  Cook,  and  Hales,  1985).  K-ATP 
channels are also activated by a  novel class of drugs known as K + channel openers 
(Edwards and Weston,  1990; Standen, Quayle, Davies, Brayden, Huang, and Nelson, 
1989).  These  agents  include  cromakalim,  a  potent  smooth  muscle  relaxant  with 
hypotensive and bronchodilatory activity in vivo, as well as diazoxide,  an antihyper- 
tensive  drug  also used  to  treat  some pancreatic  carcinomas  (Dunne  and  Petersen, 
1991). 
In  contrast,  the  pharmacology  of CFTR  CI-  channels  is  less  well  defined.  The 
search  for modulators  of CFI'R Cl-  channels  is important  in  at least two respects. 
First, no high affinity inhibitors of CFTR Cl- channels have yet been identified; such 
inhibitors  might be useful  as agents  for distinguishing  CFTR CI- channels  and  as 
probes of the mechanism of ion permeation.  Second,  novel pharmacological activa- 
tors of CFrR Cl- channels might provide an important therapy for the defective Cl- 
secretion across CF epithelia. 
Thus, the goal of this study was to examine the effect of agents that might inhibit 
or  activate  CFTR  C1-  channels.  Because  both  CFTR  and  K-ATP  channels  are 
regulated by ATP, we examined the effect of sulfonylureas and K + channel openers 
on CKTR Cl- currents measured using the whole-cell, patch-clamp technique. 
MATERIALS  AND  METHODS 
For this  study we used NIH 3T3  fibroblasts  that had been stably  infected with  a retrovirus 
expressing  either  wild-type  human  CFTR  (Gregory,  Cheng,  Rich,  Marshall,  Paul,  Hehir, 
Ostedgaard, Klinger, Welsh, and Smith,  1990) or a CFTR mutant in NBD2 (CFIR-KI250M, in 
which lysine  1250 was changed to methionine) (Anderson  et al.,  1991a). These two stable cell 
lines  were  generated with  the  generous help  of Dr.  S.  Thompson and  Dr.  R.  C.  Mulligan 
(Whitehead  Institute,  Massachusetts  Institute of Technology, Cambridge, MA). We also tran- 
siently  expressed another mutant (CFI'R-K335E, in which  lysine 335  in the first  transmem- 
brane domain was changed to glutamic acid) in HeLa cells using the vaccinia virus-T7 hybrid 
expression system (Rich et al., 1990; Elroy-Stein, Fuerst,  and Moss, 1989). CFTR, in which part 
of the R domain was deleted (amino acids  708-835; CFFRAR)  (Rich et al.,  1991), was stably 
expressed in a mouse mammary celt line (C127 cells). This stable C127 cell line was generated 
by first inserting CFTRAR cDNA in place of wild-type CFTR cDNA in a bovine papilloma virus 
(BPV)-based expression vector. The CFTRAR  plasmid was then introduced  into C127  cells 
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C127 cell line was a generous gift of Dr. R. J. Gregory and Dr. A. E. Smith (Genzyme Corp., 
Framingham, MA). Cells were maintained in culture as previously described (Rich et al.,  1990). 
Patch pipettes were back-filled with an intracellular solution containing (mM):  120 N-methyl- 
I>glucamine, 85  aspartic acid,  3  MgC12,  1 CsEGTA (ethyleneglycol-bis-(13-aminoethyl  ether) 
N, N, N', N'-tetraacetic acid, cesium salt; Sigma Chemical Co., St. Louis, MO),  1 MgATP, and 5 
TES (N-Tris(hydroxymethyl)methyl-2-aminoethane  sulfonic acid),  and pH was adjusted to 7.3 
with HCI, yielding a CI- concentration of 43 mM. By replacing K  + in the intracellular solution 
with the impermeant cation N-methyl-D-glucamine, K+-selective currents were inhibited. The 
free Ca  ~+ concentration of the intracellular solution was  < 10 -s M. 
Cells were washed in Ca  2+- and Mg2+-free phosphate-buffered saline and briefly treated with 
0.25% (wt/vol) trypsin to detach them from the plastic Petri dishes on which they were grown. 
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FIGURE  1.  Structure  of  the 
sulfonylureas and  K  ÷  channel 
openers used in this study. 
This treatment did not affect the properties of CFTR CI- currents. Small aliquots of cells were 
placed in a chamber (volume =  0.5 cm  3) mounted on the stage of an inverted microscope and 
bathed in an extracellular solution containing (mM):  140  NaCI,  1.2  MgSO4, 1.2  CaCI2, 10 
dextrose, and 10 TES (pH 7.3 with NaOH). Test solutions were gently perfused into the bath 
and removed by a vacuum pump. All solutions were filtered through 0.45-1zm filters (MiUipore 
Corp.,  Bedford,  MA)  and  experiments were  conducted  at  34-36°C  using a  temperature- 
controlled microscope stage (Brook Industries, Lake Villa, IL). 
Patch pipettes were fabricated from thin-walled borosilicate glass capillary tubing (Rochester 
Scientific Co., Rochester, NY) using a two-stage vertical pipette puller (model 750; David Kopf 
Instruments, Tujunga, CA) and coated with Sylgard (Dow Coming Corp., Midland, MI). Pipette 
tips were polished using a microforge. Patch pipettes had resistances of 2--4 MI'I when filled 
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Whole-cell membrane currents were recorded according to the method of Hamill,  Marty, 
Neher, Sakmann, and Sigworth (1981) using a List EPC-7 amplifier (Adams and List Associates, 
Ltd., Westbury,  NY).  Seals  of 10-40  GI~ were  routinely  obtained.  Cells  were  clamped  at  a 
holding potential of 0 mV and membrane currents were measured during depolarizing and 
hyperpolarizing voltage steps. 
The established  sign convention was used throughout. That is,  ionic currents produced by 
positive charge moving from intra- to extracellular solutions (anions moving in the opposite 
direction)  are  shown as positive currents.  The bath  electrode  consisted of a Ag-AgCI pellet 
connected to the bathing solution via an agar bridge filled with  1 M KCI. 
A microcomputer (IBM AT compatible)  and  the pClamp  software package (Axon Instru- 
ments,  Inc., Foster City,  CA) were used for pulse  generation,  data acquisition,  and analysis. 
Voltage-pulse protocols were applied  to the stimulus input of the List EPC-7 amplifier after 
digital-to-analog conversion using a TL-I DMA interface (Axon Instruments, Inc.). The signal 
from the  patch-damp  amplifier,  which was  filtered  at  0.5-2.5  kHz using a  variable  8-pole 
Bessel  filter (Frequency Devices  Inc., Haverhill,  MA), was simultaneously viewed on a storage 
oscilloscope and acquired using pClamp software. 
Data shown have not been capacitance or leak subtracted. Results are expressed as means -+ 
SEM of n observations. 
Adenosine trisphosphate magnesium salt (MgATP), 8-(4-chlorophenyhhio)-adenosine 3':5'- 
cyclic  monophosphate  sodium  salt  (CPT-cAMP),  forskolin,  3-isobutyl-l-methylxanthine 
(IBMX), and TES were purchased from Sigma Chemical Co. 
The chemical structures of the agents studied are shown in Fig.  1; they include tolbutamide 
(Sigma Chemical Co.), glibenclamide (Sigma Chemical Co.), diazoxide (Research Biochemicals 
Inc., Natick,  MA), BRL 38227  (lemakalim,  the biologically active enantiomer of cromakalim 
[Edwards  and  Weston,  1990],  a  generous  gift  of  SmithKline  Beecham  Pharmaceuticals, 
Betchworth, UK), and minoxidil sulphate (a generous gift of the Upjohn Company, Kalamazoo, 
MI).  Stock solutions of the sulfonylureas and diazoxide were prepared  in dimethyl sulfoxide 
and BRL 38227 in 70% (vol/vol) ethanol; minoxidil sulfate was prepared in acetone according 
to the manufacturer's instructions. Drugs were diluted in extracellular solution to achieve final 
concentrations at the time of use. The vehicle solutions did not affect CFI'R CI- currents (n = 4 
in each case). 
RESULTS 
Cells  expressing  CFTR  exhibited  little  or  no  Cl--selective  current  under  baseline 
conditions  (Fig.  2A).  Addition  of cAMP  agonists  (10  v,M  forskolin  and  100  IxM 
IBMX,  or  500  I~M  CPT-cAMP,  a  membrane-permeant  cAMP  analogue)  activated 
large Cl--selective  currents  (Fig.  2 B). The current-voltage (I-V) relationship  of the 
cAMP-regulated  CI-  current  was  linear  (Fig.  2 E)  and  the  currents  exhibited  no 
evidence ofvohage-dependent activation or inactivation. In preliminary experiments, 
CFTR C1- current levels were stable over 3-5 min after activation. 
Sulphonylurea Drugs 
We examined the effect of the sulfonylurea drugs tolbutamide and glibenclamide by 
adding them after currents were activated by cAMP agonists. Fig. 2 C shows that 500 
~M  tolbutamide  inhibited  CFTR  CI-  currents.  Inhibition  of CFI'R  CI-  currents 
showed little voltage dependence  (Fig. 2, C and E). 
Glibenclamide inhibits  K-ATP channels more potently than tolbutamide  (Ziinkler, 
Lenzen,  M~inner,  Panten,  and Trube,  1988a).  Fig.  3 C  shows that 25  I~M glibencla- 578 
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FIGURE 2.  Tolbutamide  inhibits 
CFI'R  C1-  currents.  Whole-cell 
currents  were  recorded  from  an 
NIH  3T3  fibroblast  expressing 
CFFR.  The  inset  shows  that  the 
holding  potential was  0  mV  and 
voltage was  stepped from  +50  to 
-90  mV  in  20-mV  decrements. 
Dotted  line  represents  the  zero 
current  level.  (A)  Baseline condi- 
tions. (B) Currents recorded 2 min 
after adding  10  CM forskolin and 
100  ~M  IBMX  (cAMP).  (C)  Cur- 
rents recorded 3 rain after adding 
500 I~M tolbutamide. (D) Recovery 
of currents  15  min  after washing 
the  drug  from  the  bath.  (E)  t-V 
relationship  of currents  inhibited 
by tolbutamide; current was meas- 
ured at the end of a 400-ms voltage step. Data in E are from the traces in A-D. m, baseline; ©, 
cAMP; O, cAMP +  tolbutamide; [~, cAMP wash. 
mide  also  potently  inhibited  CFTR  C1-  currents;  inhibition  showed  little  voltage 
dependence. 
Inhibition  by  both  sulfonylureas  developed  slowly;  3  min  after  adding  1  mM 
tolbutamide or 100  ~M glibenclamide, CFTR CI- currents were inhibited by  > 90%. 
A  second slower phase of current decay was also observed (not shown). This probably 
represents current "rundown",  a  phenomenon  that has been previously documented 
for CFrR  CI- channels  (Berger et al.,  1991).  CFFR CI- currents partially recovered 
from  tolbutamide  treatment  with  washes  lasting  >  10  min  (Fig.  2 D).  However, 
glibenclamide inhibition was irreversible even upon prolonged washing (Fig. 3 D). SHEPPARD  AND WELSH  K-ATP Channel Regulators Inhibit CFTR 
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FIC;U~E 3.  Glibenclamide  inhibits  CFTR 
CI- currents. Currents were recorded from 
an  NIH 3T3  fibroblast  expressing  CFTR 
as described in Fig.  2.  (A) Baseline condi- 
tions.  (B)  Currents  recorded  2  min  after 
adding  500  p~M  CPT-cAMP (cAMP).  (C) 
Currents  recorded 3 min after adding 25 
p~M glibenclamide.  (D) Currents recorded 
30  rain  after washing  the  drug  from the 
bath.  (E)  I-V relationship  of currents  in- 
hibited by glibenclamide; data are from the 
traces  shown  in  A-D.  J,  baseline;  O, 
cAMP;  @,  cAMP  +  glibenclamide;  El, 
cAMP wash. 
Sulfonylurea  inhibition  was  concentration  dependent  (Fig.  4).  The  relationship 
between drug concentration and current inhibition was fitted to the equation: 
I  (% control) =  1/{1  +  ([drug]/Ki)" }  (1) 
where Ki is the drug concentration (micromolar) causing half-maximal inhibition and 
n  is  the  Hill  coefficient.  Glibenclamide  was  more  potent  than  tolbutamide  and  for 
both drugs n was  < 1 (Table I). 
Potassium Channel Openers 
ATP-regulated  K +  channels  are  activated  by  a  family  of drugs  called  K +  channel 
openers, which include the compounds diazoxide,  BRL 38227, and minoxidil sulfate 
(Standen  et  al.,  1989;  Edwards  and Weston,  1990).  We tested  whether  K + channel 
openers could stimulate CFTR CI- channels in NIH 3T3 fibroblasts stably expressing 
CFTR.  Diazoxide  (100-1,000  IxM),  BRL  38227  (250  p.M),  and  minoxidil  sulfate 
(10-500  p.M)  had  no  effect  on  baseline  currents  (n =  3  in  each  case;  results  not 80 
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FIGURE 4.  Dose-response curves for the effect of sulfonylureas on CFTR C1- currents.  Data 
are from currents  recorded 3 rain after  adding increasing  concentrations  of tolbutamide  (A) 
and glibenclamide (B). Currents were measured at the end of 400-ms voltage steps to +50 mV 
and are expressed as percent control current. Baseline currents, which measured  < _  100 pA at 
+50  and  -90  mV,  have  not  been  subtracted.  Results  represent  the  mean  -+  SEM  of 5-12 
observations at each concentration. 
shown). However, the subsequent activation of CFTR C1- currents by cAMP-mediated 
agonists was  consistently attenuated  in  the  presence  of K  +  channel  openers when 
compared with that normally observed upon cAMP stimulation (not shown). Because 
of this result, we examined the effect of K + channel openers on CFFR CI- currents 
that had previously been activated by cAMP agonists. 
After CFFR CI- currents were activated by cAMP agonists (Fig. 5, A, D, and G) we 
added either diazoxide, BRL 38227, or minoxidil sulfate to the bathing solution (Fig. 
5,  B,  E,  and  H).  In  each  case,  CI-  current was  inhibited.  Inhibition  showed little 
voltage dependence.  As was  observed with  the  sulfonylureas,  inhibition  by the  K  + 
channel openers developed slowly; 3 rain after adding 1 mM diazoxide, 250 ~M BRL 
38227, or  100 o.M minoxidil sulfate CFFR Cl- currents were inhibited by  > 70%. A 
TABLE  I 
Effect of Sulfonflureas and K + Channel Openers on CFFR Cl-  Currents 
Drug  Ki  n  Experiments 
uM 
Tolbutamide  149.5  -,- 80.83  0.8  +- 0.1  5 
Glibenclamide  21.8  +  5,2  0.8 --- 0.1  7 
Diazoxide  259.9  --- 51.0  0.6 -+ 0.1  5 
BRL 38227  48.3 x  4.5  0.8  +- 0.2  4 
Minoxidil sulfate  37.9 4- 9.6  0.5 -+ 0.1  4 
Data from individual experiments were fitted to a linear form of Eq.  1 using a linear 
least-squares regression program to yield  drug concentration causing half-maximal 
inhibition,  Ki,  and  Hill  coefficients,  n.  The  number  of individual  experiments  is 
indicated.  From these data the tabulated mean values were derived. The results were 
calculated from currents measured at +50 mV without subtraction of residual current. SHEPPAd~,D AND WELSH  K-ATP Channel Regulators Inhibit CFTR  581 
second slower phase of current decay was also observed (not shown) which probably 
represents  current  "rundown".  Inhibition  was  poorly  reversible  over  5-min  time 
intervals (not shown); longer washes were not tested. 
Inhibition  by  K +  channel  openers  was  concentration  dependent  (Fig.  6).  The 
relationship between  drug concentration  and  current  inhibition was  fitted to  Eq.  1 
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FIGURE .5.  K  +  channel  openers  inhibit  CFFR  C1-  currents.  Traces  are  from  NIH  3T3 
fibroblasts expressing CFFR as  described in  Fig.  2.  Under  baseline conditions, membrane 
currents measured  <-+ 100  pA at  +50  and  -90  mV. A, D, and G  show CFTR CI- currents 
recorded 2 min after addition of cAMP agonists. B, E, and H  show currents recorded 3 min 
after the addition of 500  p.M diazoxide (B),  100  IxM BRL 38227  (E), and  100  p.M minoxidil 
sulfate  (H).  The  corresponding I-V relationships are  shown  in  C,  F,  and  1.  Currents  were 
measured as described in Fig. 2. 
and  the results are  shown  in Table  I.  Minoxidil sulfate was  more potent  than  BRL 
38227, which was more potent than diazoxide. In each case n  was  <  1. 
Effect of Glibenclamide on CFTR Mutants 
We were interested to learn how sulfonylureas and K ÷ channel openers interact with 
CFTR. We therefore examined the effect of glibenclamide, the most potent inhibitor 
we had identified, on CI- currents  generated by several CFFR mutants. We studied 582  THE  JOURNAL  OF  GENERAL  PHYSIOLOGY  •  VOLUME  100  •  1992 
CFTR containing mutations that affect each of the three types of domains of CFTR: 
CFFP~R  where  part  of the  R  domain  has  been  deleted  (amino  acids  708-835); 
CVFR-K335E, which contains  a  mutation in  the sixth putative membrane-spanning 
sequence;  and  CFTR-K1250M,  which  contains  a  mutation in  the  second  NBD.  We 
thought  it  possible  that  if  glibenclamide  specifically  interacts  with  one  of  these 
domains, its inhibitory properties might be altered. 
CFTR~R  forms  C1-  channels  that  are  active  independent  of cAMP  stimulation 
(Rich et al.,  1991). This is illustrated in Fig. 7 A,which shows a family of CFTR~R CI- 
currents  recorded  in  the  absence  of cAMP agonists  (as  in  all previous  studies,  the 
pipette contained  1 mM MgATP). Although CFTP~R C1- channels are constitutively 
active, they possess the same biophysical properties as wild-type CFTR CI- channels: 
linear I-V relationship,  no evidence of voltage-dependent activation or inactivation, 
small single-channel  conductance,  selectivity for anions  over cations,  and  an anion 
permeability sequence  of Br-  >  C1-  >  I-  (see  Rich et al.,  1991;  Anderson  et al., 
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FIGURE 6.  Dose-response curves for the effect of K + channel openers on CFTR CI- currents. 
Data are for diazoxide (A), BRL 38227 (B), and minoxidil sulfate (C), measured as described in 
Fig. 4,  and  are  expressed  as  percent  control  current.  Baseline  currents,  which  measured 
< +-- 100 pA at +50 and -90 mV, have not been subtracted. Results represent the mean --- SEM 
of four to eight observations at each concentration. 
1991a;  and  Fig.  7, A  and  C).  The  small,  slowly activating and  inactivating current 
components  observed  at  large  positive  and  negative  potentials  (Fig.  7 A)  were 
observed  infrequently,  and  are  also  observed  in  some  cells  expressing  wild-type 
CFTR (Anderson et al.,  1991b;  Rich et al.,  1991). 
Although deletion of the R domain did not prevent inhibition by glibenclamide, its 
inhibitory properties differed from those observed with wild-type CFTR.  Inhibition 
was significantly more potent at hyperpolarizing voltages than at equivalent depolar- 
izing voltages (Fig. 7, B and C). 
CFFR-K335E  forms CI-  channels  that  are  similar  to wild-type  channels,  except 
that the anion selectivity is altered such that I-  >  Br-  >  C1- and currents show some 
outward  rectification  (Anderson  et al.,  1991b  and  Fig.  7,  D  and F).  Glibenclamide 
inhibited CFTR-K335E CI- currents, and the effect was similar to that observed with 
wild-type CFTR (Fig.  7, E  and F). 
Comparison  with  ATP-dependent  transporters  suggest  that  mutations  in  the 
second NBD, such as CFTR-K1250M, are likely to abolish or impair the function of SHEPP~LRD  AND  WELSH  K-ATP Channel Regulators Inhibit CFTR  583 
NBD2 (Anderson et al.,  1991a). Nevertheless, CFFR-K1250M produces CI- channels 
that have cAMP-dependent regulation and biophysical properties  that are similar to 
wild-type  CFFR  (see  Anderson  et  al.,  1991a,  and  Fig.  7,  G  and  I).  Inhibition  of 
CFTR-K1250M  CI-  currents  by  glibenclamide  was  similar  to  that  observed  with 
wild-type CYI'R (Fig.  7, H  and I). 
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FIGURE 7.  Glibenclamide inhibits CFTR mutants. Traces are from C127 cells stably express- 
ing CFTP-~R (A-C), HeLa cells transiently expressing CFFR-K335E (D-F), and NIH 3T3 cells 
stably  expressing  CFIR-K1250M  (G-I).  Currents  were  measured  as  described  in  Fig.  2. 
CFFRAR currents were recorded in the absence of cAMP,  but for CFFR-K335E and CFTR- 
K1250M  currents  cAMP agonists were present.  Before addition  of cAMP agonists,  currents 
measured  <-+100 pA at +50 and  -90 inV. B, E, and H  show currents recorded 3 rain after 
adding 100 p,M glibenclamide. The corresponding I-V relationships of C FFR mutants inhibited 
by glibenclamide are shown in C, F, and I. Currents were measured as described in Fig. 2. 
Fig.  8  shows  the  relationship  between  glibenclamide  concentration  and  current 
produced  by  wild-type  and  CFTR  mutants.  Data  for  steady-state  current  values 
measured  at  +50  and  -90  mV  are  shown  for wild-type  CF-FR  (A),  CFTRAR  (B), 
CFFR-K335E (C),  and CFTR-K1250M  (D). The dose-response  curves for wild-type 
CFFR, CFTR-K335E,  and CFTR-K1250M were similar. Although the effect was not 
marked, in each case inhibition was slightly more potent at -90  mV than at +50 inV. 584 
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FIGURE  8.  Dose-response curves for inhibition of CFTR mutants by glibenclamide. Data were 
obtained and expressed as described in Fig. 4.  Baseline currents, which measured  <--100 pA 
at  +50  and  -90  mV,  have  not  been  subtracted.  (A)  Wild-type  CFTR;  (B)  CFTR~R;  (C) 
CFTR-K335E; (D) CFFR-K1250M.  Results represent the mean -- SEM of 3-11  observations at 
each concentration. 
With CFTRAR, glibenclamide was substantially more potent at hyperpolarizing (-90 
mV) than at depolarizing (+50 mV) voltages (P <  0.05 at 100 I~M glibenclamide). In 
addition,  100 I~M glibenclamide inhibited less current at +50 mV in CFTRAR than in 
wild-type CFTR (P =  0.005). 
The data for all the mutants except CFI'RAR were well fitted by Eq.  1 (Table II). 
Half-maximal inhibition by glibenclamide was similar in all cases, occurring at  ~ 20 
TABLE  I1 
Effect of Glibenclamide on CFTR Mutants 
4-50 mV  -90 mV 
Mutant  Experiments 
Ki  n  Ki  n 
my/  u2v/ 
CFTR  21.8 ±  5.2  0.8 -  0.1  19.0 -  5.6*  0.7  ±  0.1  7 
CFTR-K335E  25.9 ± 4.1  0.9 ±  0.I  20.4  +-- 3.7*  0.9 ±  0.1  6 
CFTR-K1250M  16.8 _  4.2  0.8 ±  0.1  31.2  ±  2.5  1.0 -  0.1  5 
Ki and n values were calculated as described in Table I for currents measured at +50 
and  -90  mV for  the  number of experiments  listed.  Asterisks  indicate  statistically 
significant difference between Ki values (P  <  0.05). SHEPPARD AND WELSH K-ATP Channel Regulators Inhibit CFTR  585 
~M;  n  values were  also  comparable  and  less  than  1.  Half-maximal inhibition by 
glibenclamide,  measured  at  -90  mV,  showed  a  small  but  statistically significant 
increase  in  potency  compared  with  that  at  +50  mV  for  wild-type  CFTR  and 
CFTR-K335E, but not CFFR-K1250M. 
DISCUSSION 
The  goal of this  study was  to  find  modulators of CFTR  CI-  channels. The  data 
demonstrate that agents that regulate the opening of K-ATP channels also inhibit 
CF-I'R CI-  channels with  a  rank order of potency of:  glibenclamide  >  minoxidil 
sulfate ---- BRL 38227  >  tolbutamide  >  diazoxide. Thus, these agents have a wider 
specificity of action than previously recognized. Glibenclamide represents  a  potent 
blocker of the CFFR CI- channel. 
Comparison of K-ATP Channels  and CFTR Cl- channels 
Our  study  of  agents  that  modulate  K-ATP  channel  activity  was  prompted  by 
similarities between K-ATP channels and CFFR. K-ATP channels have not yet been 
sequenced and probably represent a heterogeneous class of K  ÷ channels since there 
are tissue-specific differences in their biophysical properties and regulation (Ashcroft 
and Ashcroft, 1990).  Nevertheless, K-ATP channels share some functional properties 
with  CFTR  CI-  channels.  Both  CF-FR  and  K-ATP channels  can  be  regulated  by 
PKA-dependent phosphorylation (Ribalet,  Ciani,  and  Eddlestone,  1989;  Berger et 
al.,  1991;  Tabcharani  et  al.,  1991).  In  addition,  both  channels  are  relatively 
insensitive  to  changes  in  membrane  potential  and  to  the  intracellular  free  Ca  2+ 
concentration (Cook and  Hales,  1984;  Anderson et  al.,  1992).  The  most notable 
similarity between these channels is regulation by intracellular ATP. The  effect of 
ATP, however, differs for the two types of channel: ATP activates CFTR C1- channels, 
whereas it inhibits K-ATP channels (Noma,  1983; Cook and Hales,  1984;  Anderson 
et al.,  1991a). Another difference is that hydrolyzable nucleoside triphosphates are 
required  to  regulate  CFTR,  whereas  nonhydrolyzable  analogues  of ATP  inhibit 
K-ATP  channels  (Dunne,  West-Jordan,  Abraham,  Edwards,  and  Petersen,  1988; 
Anderson et al.,  1991a). 
The modulation of K-ATP channels in excitable cells by intracellular ATP couples 
cellular metabolism and electrical activity. For example, K-ATP channels establish the 
resting  membrane  potential  in  pancreatic  [3  cells  and  their  closure  by  glucose 
metabolites initiates insulin secretion (see Dunne and Petersen,  1991, for review). In 
contrast,  in  cardiac  myocytes  K-ATP  channels  are  normally  quiescent  but  they 
activate  during  ischemia  to  increase  K +  efflux and  decrease  the  action  potential 
duration  (Gasser  and  Vaughan-Jones,  1990).  These  effects  are  believed  to  be 
important in preserving cellular homeostasis. It has been speculated that CFTR CI- 
channels  fulfill  a  similar  homeostatic  mechanism  in  epithelia  (Quinton,  1990). 
Regulation of CFTR CI- channels by intracellular ATP may represent a  strategy by 
which secretory epithelial cells balance the rate of transepithelial CI- secretion with 
cellular ATP levels, thereby controlling cell volume and ionic composition (Quinton, 
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Effect of K + Channel Regulators  on  CFTR  CI-  Channels 
Tolbutamide and  glibenclamide  inhibit  K-ATP channels  in  pancreatic  [3 cells with 
half-maximal inhibition at  ~4  ~M  and  4  nM,  respectively (Ziinkler et al.,  1988a). 
However, in cardiac myocytes, higher concentrations of sulfonylureas are required to 
block K-ATP channels:  Belles, Hescheler, and Trube (1987) reported half-maximal 
inhibition of whole-cell K-ATP currents at  > 300 ~M tolbutamide. The sulfonylureas 
tolbutamide and glibenclamide inhibited CFTR C1- currents at half-maximal concen- 
trations of  ~ 150 and  20  p,M, respectively. Inhibition showed little voltage depen- 
dence, developed slowly, and was reversible with tolbutamide but not with glibencla- 
mide.  These  characteristics  are  similar  to  the  effect  of sulfonylureas  on  K-ATP 
channels  (Belles et al.,  1987; Gillis,  Gee, Hammoud,  McDaniel,  Falke,  and  Misler, 
1989). 
In  contrast  to  their  effect  on  K-ATP  channels,  diazoxide,  BRL  38227,  and 
minoxidil  sulfate  did  not  stimulate  CFFR  CI-  channels,  either under baseline  or 
cAMP-stimulated conditions. Instead, these agents inhibited CFFR C1-  channels. As 
observed with  the sulfonylureas, blockade showed little voltage dependence, devel- 
oped  slowly,  and  was  poorly reversible.  The  potency of K +  channel  openers  for 
inhibition  of CFFR  C1-  channels  (minoxidil  sulfate  [40  o,M]  --- BRL  38227  [50 
p~M] >  diazoxide  [250  p,M])  was  weaker  than  their  effect on  K-ATP  channels  in 
smooth muscle. In vascular smooth muscle,  1 p,M cromakalim (Standen et al.,  1989) 
and 2 p~M minoxidil sulfate (Leblanc, Wilde, Keel, and Hume,  1989) activate K-ATP 
channels, and in pancreatic 13 cells 100 p~M diazoxide (Dunne, AspinaU, and Petersen, 
1990) stimulates K-ATP channels.  However, there is marked tissue specificity in the 
action of K ÷ channel openers; for example, 800 pLM cromakalim is needed to match 
the activation of K-ATP channels by 100 p,M diazoxide in pancreatic 13 cells (Dunne 
et al.,  1990). 
The  activation of K-ATP channels  by  K +  channel  openers  is  dependent  on  the 
presence  of cytosolic factors.  In  the  absence  of intracellular ATP,  diazoxide  and 
cromakalim are ineffective. However, high concentrations of ATP are also inhibitory, 
suggesting  a  competitive interaction between ATP and  K + channel  openers  (Koz- 
lowski,  Hales, and Ashford, 1989; Dunne et al., 1990). Diazoxide is also ineffective in 
the absence of intracellular Mg  2÷  (Kozlowski et al.,  1989). The activation of K-ATP 
channels only occurs in the presence of cytosolic MgATP; in its absence K + channel 
openers are either without effect or inhibit K-ATP channels (Kozlowski et al.,  1989; 
Dunne,  1990). Interestingly, diazoxide blocks cardiac K-ATP channels regardless of 
whether or not MgATP is present (Faivre and Findlay, 1989). K + channel openers are 
also  ineffective  when  nonhydrolyzable  ATP  analogues  are  substituted  for  ATP, 
suggesting  that  the  drugs  may  act  on  a  phosphorylated  form  of  the  channel 
(Kozlowski et al.,  1989; Dunne et al.,  1990). 
Sulfonylureas  are  highly  lipid  soluble,  suggesting  that  they  may  permeate  the 
plasma  membrane to exert their 
sulfonylureas are equally effective 
intra- or extracellular membrane 
addition,  increasing  extracellular 
K-ATP channels,  suggesting  that 
effect. This idea is  supported by the finding that 
in inhibiting K-ATP channels when applied to the 
surface (Belles et al.,  1987;  Gillis et al.,  1989).  In 
pH  slows  the  onset  of tolbutamide  inhibition  of 
the  undissociated  form of the  drug  is  the  active SHEPPARD AND WELSH  K-ATP Channel Regulators Inhibit CFTR  587 
moiety (Z~inkler,  Trube, and Panten,  1989). The slow onset of sulfonylurea inhibition 
of CFTR CI-  currents is  consistent with the idea  that  the  drugs  permeate the cell 
membrane to exert their effect. 
The action of sulfonylureas on K-ATP channels is  also regulated by intracellular 
compounds. Cytosolic ADP increases the tolbutamide sensitivity of K-ATP channels in 
pancreatic 13 cells, while other nucleotides are without effect (Ziinkler, Lins, Ohno- 
Shosaku,  Trube,  and  Panten,  1988b).  However,  in  cardiac  myocytes the  converse 
effect is seen; ADP attenuates glibenclamide inhibition of K-ATP channels (Venkatesh 
and Weiss,  1991).  During whole-cell recordings ATP in  the  pipette-filling solution 
may be hydrolyzed to ADP by enzymes remaining in the cell. It is therefore possible 
that the Kn values for CFTR CI- current inhibition by sulfonylureas and K + channel 
openers were influenced by the composition of the pipette-filling solution. The Hill 
coefficient for inhibition of CFFR C1-  currents was  < 1 for all the drugs tested. This 
suggests  that cooperativity is not important for the interaction of these agents with 
CFI'R.  Similar  values  of  Hill  coefficients  have  been  reported  for  the  effect  of 
tolbutamide  and  diazoxide  on  K-ATP  channels,  although  higher values  were  re- 
ported for glibenclamide (Ziinkler et al.,  1988a). 
In  an  attempt  to  gain  some  insight  into  how  these  agents  might  interact with 
CFTR, we examined the effect of glibenclamide, the most potent inhibitor we had 
identified, on CI- currents generated by several CFTR mutants. We chose mutations 
in  each  of the  three  types  of domains  of CFTR.  Inhibition  of CFTR-K335E  and 
CFTR-K1250M  CI-  currents  by  glibenclamide  resembled  that  of wild-type CFFR. 
This suggests  that residues  K335E and  K1250M do not form a  critical part of the 
glibenclamide  interaction  site.  Nevertheless,  other residues  within  the  membrane- 
spanning and nucleotide-binding domains may contribute to the interaction. 
Glibenclamide  also  inhibited  CFTRAR  CI-  currents,  but  the  inhibition  showed 
significant voltage dependence, with a  greater potency at hyperpolarizing voltages. 
This  result  suggests  that  the  R  domain  in  some  way  affects  the  response  to 
glibenclamide such that deletion of part of the R domain partially relieves the block 
of CFTR CI-  currents by glibenclamide at depolarized voltages. However, the data 
also indicate that the major part of the R domain is not required for glibenclamide 
interaction. At present we do not have an explanation for this interesting observation. 
Glibenclamide represents a potent inhibitor of CFTR CI- currents. In comparison, 
millimolar  concentrations  of extracellular  diphenylamine-2-carboxylate  (DPC)  are 
required  to  block  CFTR  CI-  currents  by  ~80%  (Anderson  et  al.,  1991c,  1992; 
McCarty,  Cohen,  Quick,  Riordan,  Davidson,  and  Lester,  1992);  the  arylaminoben- 
zoate NPPB (100-200 IxM) applied extracellularly is reported to be less efficient than 
DPC (McCarty et al.,  1992).  Inhibition by DPC  is voltage dependent with stronger 
blockade at negative potentials, suggesting that it interacts with the channel from the 
intracellular surface (McCarty et al.,  1992). Extracellular DIDS, a stilbene-disulfonic 
acid  derivative that  blocks  several types of epithelial CI-  channels  does  not affect 
CFFR CI- currents at concentrations of 500 IxM (Kartner et al.,  1991; Anderson et 
al.,  1992).  Similarly,  the  C1-  channel blockers Zn  2+  and  the indanyloxyacetic acid 
derivative IAA-94 are ineffective inhibitors when applied extracellularly at concentra- 
tions of 100 and 40 I~M, respectively (Anderson et al.,  1992). Thus, glibenclamide is 
the most potent inhibitor of cF'rR identified to date. 588  THE JOURNAL OF  GENERAL PHYSIOLOGY • VOLUME 100 •  1992 
Implications for Disease 
One of our initial goals in this study was to find agents that would activate CFTR. We 
thought that the discovery of novel pharmacological activators of CFTR CI- channels 
might provide a  new therapeutic strategy for treating CF patients. Although we did 
not find agents that activate CFTR, the finding that CFTR is inhibited by sulfonyl- 
ureas and K + channel openers suggests an interaction and raises the possibility that 
related agents might prove to be valuable activators of CFFR. A similar relationship 
between channel  activators and  inhibitors exists with the  dihydropyridine class  of 
Ca  2+ channel agonists and antagonists (Hess, Lansman, and Tsien,  1984). 
It is,  however, interesting to consider the possibility that these or related agents 
might be  of value  in  another  disease  that probably  involves CFTR CI-  channels. 
CFFR is  located within the  apical membrane  of Cl--secreting  intestinal epithelial 
cells  (Crawford,  Maloney,  Zeitlin,  Guggino,  Hyde,  Turley,  Gatter,  Harris,  and 
Higgins,  1991;  Denning,  Ostedgaard,  Cheng,  Smith,  and Welsh,  1992).  Chloride 
efflux  through  CFTR  C1-  channels  probably  contributes  to  the  watery  diarrhea 
caused  by  microbial  toxins  such  as  cholera  toxin  and  heat-stable  Escherichia  coli 
enterotoxin (Fondacaro, 1986). The development of therapeutically active blockers of 
CFTR CI- channels might therefore provide a treatment for some forms of diarrhea. 
The potency of glibenclamide inhibition of CFTR CI- channels suggests that it may 
be of value in the design and synthesis of such drugs. 
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